IOZK analysis confirms good tolerability of IOZK immunotherapy in diffuse intrinsic pontine glioma (DIPG)
The IOZK team, together with an international group of scientists from Germany, Switzerland, and the USA, has published a retrospective analysis on the use of IOZK immunotherapy in diffuse intrinsic pontine glioma (DIPG). It demonstrates the good tolerability and potential clinical benefits of the combination of vaccination with dendritic cells, oncolytic virotherapy with Newcastle disease virus, and modulated electrohyperthermia.
